BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10198785)

  • 1. Mechanism of hepatoprotective action of bile salts in liver disease.
    Stiehl A; Benz C; Sauer P
    Gastroenterol Clin North Am; 1999 Mar; 28(1):195-209, viii. PubMed ID: 10198785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of ursodeoxycholic acid in patients with liver disease.
    Angulo P
    Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
    Trauner M; Graziadei IW
    Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
    Pusl T; Beuers U
    World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
    Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
    Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New aspects of pharmacological effects of ursodeoxycholic acid].
    Radchenko VG; Seliverstov PV; Sitkin SI
    Eksp Klin Gastroenterol; 2014; (8):4-10. PubMed ID: 25911905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
    Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
    Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ursodeoxycholic acid: history and clinical implications].
    Beuers U; Trampert DC
    Ned Tijdschr Geneeskd; 2022 Sep; 166():. PubMed ID: 36300467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
    Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
    BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases.
    Festi D; Montagnani M; Azzaroli F; Lodato F; Mazzella G; Roda A; Di Biase AR; Roda E; Simoni P; Colecchia A
    Curr Clin Pharmacol; 2007 May; 2(2):155-77. PubMed ID: 18690863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with ursodeoxycholic acid in cholestatic liver disease.
    Van de Meeberg PC; van Erpecum KJ; van Berge-Henegouwen GP
    Scand J Gastroenterol Suppl; 1993; 200():15-20. PubMed ID: 8016564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation.
    Sokolovic D; Nikolic J; Kocic G; Jevtovic-Stoimenov T; Veljkovic A; Stojanovic M; Stanojkovic Z; Sokolovic DM; Jelic M
    Drug Chem Toxicol; 2013 Apr; 36(2):141-8. PubMed ID: 22385135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ursodeoxycholic acid reduces expression of heat shock proteins in primary biliary cirrhosis.
    Sakisaka S; Koga H; Sasatomi K; Ohishi M; Kawaguchi T; Harada M; Taniguchi E; Uchimura Y; Ueno T; Sata M; Tanikawa K
    Liver; 2000 Feb; 20(1):78-87. PubMed ID: 10726964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ursodeoxycholic acid in the treatment of cholestatic liver diseases].
    Arrese M; Accatino L
    Rev Med Chil; 1993 Apr; 121(4):439-46. PubMed ID: 8272619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
    Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
    Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.